Vericel Corporation (ATQP)

Overview

Vericel Corporation is a commercial-stage biopharmaceutical company dedicated to innovating cellular therapies for the sports medicine and severe burn care markets within the United States. Originating from its foundation in 1989 and previously known as Aastrom Biosciences, Inc., the company has grown its footprint in the therapeutic landscape, focusing on delivering transformative treatments. With its headquarters in Cambridge, Massachusetts, Vericel Corporation is at the forefront of cellular therapy research, development, manufacture, and distribution, aiming to address significant unmet medical needs in its chosen markets.

Products and Services

• MACI

  MACI represents an innovative autologous cultured chondrocytes product, presented on a porcine collagen membrane. It is targeted at the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee. This cell therapy innovation aims to facilitate the natural regeneration process of the knee cartilage, offering a sophisticated solution to individuals struggling with knee cartilage issues.

• Epicel

  Epicel is a permanent skin replacement humanitarian use device, designed for the treatment of adult and pediatric patients suffering from deep-dermal or full-thickness burns. This product marks a significant advancement in severe burn care, providing a critical solution for patients in need of extensive skin repair and replacement, marking a pivotal achievement in the field of regenerative medicine.

• NexoBrid

  NexoBrid, currently in its preapproval stage, is a biological orphan product formulated for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. It represents Vericel Corporation's ongoing commitment to addressing the needs of burn victims through cutting-edge biological treatments, providing a new avenue for burn care that prioritizes efficient eschar removal without the need for extensive surgical intervention.